Tracked deals
7
7 tracked deals across 2022-2024.
Methuen, Massachusetts, United States
At Alcanza, we believe in the power of clinical research to move healthcare forward for all patients; because research is the first step in bringing approved treatments to market, we encourage everyone to learn more about participating.
Tracked deals
7
7 tracked deals across 2022-2024.
Recent pace
0
0 tracked deals announced in the last 12 months.
Deal mix
Buyout
4 buyout · 3 addon
Last 3 years
Supporting Data
Alcanza Clinical Research has acquired North Georgia Clinical Research (NGCR), an investigator site based in Woodstock, Georgia. The acquisition expands Alcanza's investigator-site network in the Atlanta metro and rural Georgia areas to improve patient access and diversity for biopharmaceutical clinical trials.
Alcanza Clinical Research, an integrated investigator site network, has acquired Kansas City Research Institute (KCRI), a Phase II–IV clinical research site based in Kansas City, Missouri. The acquisition expands Alcanza's Midwest footprint and therapeutic capabilities in gastroenterology, hepatology and metabolic diseases while increasing trial access for underrepresented patient populations.
Alcanza Clinical Research has acquired FDI Clinical Research, a multi-specialty clinical research site based in San Juan with an additional site in Mayagüez, Puerto Rico. The acquisition expands Alcanza’s investigator site network into Puerto Rico, adding Phase I capability and broader therapeutic coverage to reach more diverse patient populations for sponsors and CROs.
Alcanza Clinical Research, a portfolio company of Martis Capital, has acquired Innovation Medical Research Center, a multi-specialty clinical research site located in Palmetto Bay, Florida. The add-on expands Alcanza’s therapeutic-area capabilities and patient diversity across its investigator site network as part of an ongoing roll-up strategy.
Alcanza Clinical Research has acquired Accel Research Sites Network, a Florida-headquartered multi-specialty clinical research site network with 22 locations across the Southeast U.S. Accel's operations will be integrated into Alcanza's centralized platform while retaining its brand, expanding Alcanza's geographic footprint, therapeutic capabilities, and access to diverse patient populations.
Alcanza Clinical Research has acquired Charlottesville Medical Research, adding the Charlottesville, Virginia community-based clinical research site to its integrated investigator site network. The deal expands Alcanza’s geographic reach and inclusive research capabilities to improve access to Phase II-IV trials for under-represented patient populations.
M3-Wake Research, part of M3 Inc.'s U.S. research network, has acquired Multi-specialty Research Associates (MSRA) of Lake City, Florida. The acquisition adds an additional site to Wake Research's national footprint, expanding geographic coverage and trial access in Florida.
Turn tracked acquisition activity into an outreach-ready buyer list.